-
Posted: January 12th, 2021, 3:00pm GMT
Condition: Merkel Cell Carcinoma
Intervention: Other: Samples
Sponsors: University Hospital, Tours; European Academy of Dermatology and Venerology
Not yet recruiting
-
Posted: October 16th, 2020, 2:00pm GMT
Conditions: Merkel Cell Carcinoma; Small Cell Lung Cancer
Interventions: Biological: XmAb18087; Drug: XmAb18087 ± Pembrolizumab
Sponsors: Xencor, Inc.; ICON plc
Not yet recruiting
-
Posted: September 16th, 2020, 2:00pm GMT
Condition: Solid Tumor, Adult
Interventions: Drug: FT516; Drug: Avelumab; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: IL-2
Sponsor: Fate Therapeutics
Recruiting
-
Posted: May 19th, 2020, 2:00pm GMT
Condition: Merkel Cell Carcinoma
Intervention: Drug: domatinostat in combination with avelumab
Sponsor: 4SC AG
Recruiting
-
Posted: March 2nd, 2020, 3:00pm GMT
Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Merkel Cell Carcinoma, Stage III; Neuroendocrine Tumors; Carcinoma Neuroendocrine Skin
Interventions: Drug: Avelumab; Drug: Placebo
Sponsor: Melanoma and Skin Cancer Trials Limited
Recruiting
-
Posted: February 19th, 2020, 3:00pm GMT
Conditions: Pulmonary Neuroendocrine Neoplasm; Pheochromocytoma; Paraganglioma; Thymus Carcinoid; Unknown Primary Tumors; Neuroendocrine Tumors; Neuroendocrine Skin Carcinoma; Neuroendocrine Breast Tumor; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Neoplasm of Ovary
Intervention: Drug: 177Lu-DOTATOC
Sponsor: Excel Diagnostics and Nuclear Oncology Center
Recruiting
-
Posted: February 17th, 2020, 3:00pm GMT
Conditions: Advanced Solid Tumors; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma, HCC; Cervical Cancer; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma; Cyclin-dependent Kinase 12 Mutated Tumors; Basal Cell Carcinoma (Unresectable or Metastatic); Sarcomatoid Renal Cell Carcinoma; Clear Cell Ovarian or Endometrial Carcinoma; Anal Carcinoma; Squamous Cell Penile Carcinoma; DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Intervention: Drug: INCB099318
Sponsor: Incyte Corporation
Not yet recruiting
-
Posted: February 10th, 2020, 3:00pm GMT
Condition: Metastatic Merkel Cell Carcinoma
Interventions: Drug: Avelumab; Radiation: External Beam Radiation Therapy (EBRT); Radiation: Lutetium-177 (177Lu)-DOTATATE
Sponsor: Melanoma and Skin Cancer Trials Limited
Recruiting
-
Posted: February 7th, 2020, 3:00pm GMT
Conditions: Cancer; Neoplasms; Metastatic Cancer; Triple Negative Breast Cancer; Gastric Cancer; Cervical Cancer; Ovarian Cancer; Hepatocellular Carcinoma; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma; Urothelial Neoplasm; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Locally Advanced Solid Tumor; Locally Advanced Malignant Neoplasm; Squamous Cell Carcinoma; Sarcoma; Merkel Cell Carcinoma; Bladder Cancer
Interventions: Drug: OC-001; Drug: OC-001 in Combination
Sponsor: Ocellaris Pharma, Inc.
Recruiting
-
Posted: January 29th, 2020, 3:00pm GMT
Conditions: Breast Cancer; Gastric Cancer; Chordoma; Lung Cancer; Ovarian Cancer; Prostate Cancer; Colorectal Cancer; Pancreatic Cancer; Hepatocellular Cancer; Merkel Cell Carcinoma; Small-cell Lung Cancer
Intervention: Biological: TAEK-VAC-HerBy
Sponsor: Bavarian Nordic
Recruiting
-
Posted: January 27th, 2020, 3:00pm GMT
Conditions: Advanced Solid Tumor; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma; Cervical Cancer; HepatoCellular Carcinoma; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma
Intervention: Drug: INCB099280
Sponsor: Incyte Corporation
Recruiting
-
Posted: December 5th, 2019, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Carcinoma (NSCLC); Renal Cell Carcinoma (RCC); Small-cell Lung Cancer; Head and Neck Squamous Cell Cancer; Classical Hodgkin Lymphoma; Primary Mediastinal Large B-Cell Lymphoma; Urothelial Carcinoma; Microsatellite Instability-High Cancer; Gastric Cancer; Esophageal Cancer; Cervical Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Brain Metastases, Adult
Intervention: Combination Product: LITT + Pembrolizumab
Sponsors: University of Florida; Monteris Medical
Recruiting
-
Posted: November 12th, 2019, 3:00pm GMT
Conditions: Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma
Intervention: Biological: IFx-Hu2.0
Sponsors: Morphogenesis, Inc.; H. Lee Moffitt Cancer Center and Research Institute; University of Southern California
Recruiting
-
Posted: October 4th, 2019, 2:00pm GMT
Conditions: Melanoma; Breast Cancer; Merkel Cell Carcinoma; Squamous Cell Cancer; Non Small Cell Lung Cancer; Cervical Cancer; Urothelial Carcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Small-cell Lung Cancer; Microsatellite Instability High; Gastric Cancer; Esophageal Cancer
Interventions: Device: Echopulse; Drug: Imiquimod; Drug: Standard of Care PD-1 Therapy
Sponsors: Craig L Slingluff, Jr; Theraclion
Recruiting
-
Posted: May 2nd, 2019, 2:00pm GMT
Conditions: Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Sarcoma; Mesothelioma; Neuroendocrine Tumors; Squamous Cell Cancer; Merkel Cell Carcinoma; Mismatch Repair Deficiency; Microsatellite Instability
Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL); Drug: Fludarabine + Cyclophosphamide combination
Sponsor: Udai Kammula
Recruiting
-
Posted: February 25th, 2019, 3:00pm GMT
Condition: Merkel Cell Carcinoma
Interventions: Biological: Avelumab; Biological: N-803; Biological: haNK™
Sponsors: NantKwest, Inc.; NantCell, Inc.
Recruiting
-
Posted: February 15th, 2019, 3:00pm GMT
Conditions: Advanced Solid Tumors; Lymphoma; Gastric Cancer; Colorectal Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; EGFR Positive Solid Tumor; HER2-positive Breast Cancer; Hepatocellular Carcinoma; Small Cell Lung Cancer; Renal Cell Carcinoma; Pancreas Cancer; Melanoma; NSCLC; Urothelial Carcinoma; Cervical Cancer; Microsatellite Instability; Merkel Cell Carcinoma
Interventions: Drug: FT500; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Atezolizumab; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: IL-2
Sponsor: Fate Therapeutics
Recruiting
-
Posted: December 20th, 2018, 3:00pm GMT
Condition: Merkel Cell Carcinoma
Intervention: Drug: Pembrolizumab (MK-3475)
Sponsor: Merck Sharp & Dohme Corp.
Recruiting
-
Posted: September 26th, 2018, 2:00pm GMT
Conditions: Advanced or Metastatic Merkel Cell Carcinoma; Advanced or Metastatic Cutaneous Squamous Cell Carcinoma; Advanced or Metastatic Melanoma; Advanced or Metastatic Head and Neck Squamous Cell Carcinoma; Advanced or Metastatic Solid Tumors
Interventions: Drug: Cavrotolimod; Biological: Pembrolizumab; Biological: Cemiplimab
Sponsor: Exicure, Inc.
Recruiting
-
Posted: June 4th, 2018, 2:00pm GMT
Conditions: Malignant Melanoma; Merkel Cell Carcinoma
Intervention: Diagnostic Test: Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)
Sponsor: University Hospital Inselspital, Berne
Recruiting
-
Posted: June 4th, 2018, 2:00pm GMT
Conditions: Solid Tumor; Lymphoma
Intervention: Drug: Ad-p53
Sponsor: MultiVir, Inc.
Recruiting
-
Posted: February 19th, 2018, 3:00pm GMT
Conditions: Melanoma; Merkel Cell Carcinoma; Triple Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Colorectal Cancer; Sarcoma
Interventions: Drug: NKTR-262; Drug: bempegaldesleukin; Drug: nivolumab
Sponsor: Nektar Therapeutics
Recruiting
-
Posted: December 12th, 2017, 3:00pm GMT
Conditions: Autoimmunity; Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma of the Skin; Basal Cell Carcinoma; Skin Cancer
Intervention: Biological: Immunotherapy
Sponsor: Washington University School of Medicine
Recruiting
-
Posted: August 2nd, 2017, 2:00pm GMT
Conditions: Non-Small Cell Lung Cancer; Malignant Melanoma; Head and Neck Squamous Cell Carcinoma; Classical Hodgkin Lymphoma; Urothelial Carcinoma Bladder; DNA Repair-Deficiency Disorders
Interventions: Drug: L-NMMA; Drug: Pembrolizumab
Sponsor: Jorge G. Darcourt
Recruiting
-
Posted: July 25th, 2017, 2:00pm GMT
Conditions: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer
Interventions: Drug: N-803 + Pembrolizumab; Drug: N-803 + Nivolumab; Drug: N-803 + Atezolizumab; Drug: N-803 + Avelumab; Drug: N-803 + Durvalumab; Drug: N-803 + Pembrolizumab + PD-L1 t-haNK; Drug: N-803 + Nivolumab + PD-L1 t-haNK; Drug: N-803 + Atezolizumab + PD-L1 t-haNK; Drug: N-803 + Avelumab + PD-L1 t-haNK; Drug: N-803 + Durvalumab + PD-L1 t-haNK
Sponsor: Altor BioScience
Recruiting
-
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Malignant Mesothelioma, Advanced; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Classical Hodgkin Lymphoma; Cutaneous Squamous Cell Carcinoma; Non Hodgkin Lymphoma; Endometrial Cancer
Intervention: Drug: CK-301 (cosibelimab)
Sponsors: Checkpoint Therapeutics, Inc.; Novotech (Australia) Pty Limited
Recruiting
-
Posted: April 24th, 2017, 2:00pm GMT
Conditions: Advanced Malignancies; Metastatic Cancer
Interventions: Drug: INCAGN01876; Drug: Nivolumab; Drug: Ipilimumab
Sponsor: Incyte Biosciences International Sàrl
Recruiting
-
Posted: March 8th, 2017, 3:00pm GMT
Conditions: Appendix Adenocarcinoma; Human Papillomavirus-Related Anal Squamous Cell Carcinoma; Human Papillomavirus-Related Cervical Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis; Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma; Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Merkel Cell Carcinoma; Recurrent Nasopharynx Carcinoma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Stage III Merkel Cell Carcinoma AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
-
Posted: March 7th, 2017, 3:00pm GMT
Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting
-
Posted: March 6th, 2017, 3:00pm GMT
Conditions: Merkel Cell Carcinoma; Skin Cancer
Interventions: Drug: Nivolumab; Drug: Ipilimumab; Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb
Recruiting
-
Posted: December 22nd, 2016, 3:00pm GMT
Condition: Advanced Solid Tumors
Interventions: Drug: Venetoclax; Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting
-
Posted: December 1st, 2016, 3:00pm GMT
Conditions: Adenoid Cystic Skin Carcinoma; Adnexal Carcinoma; Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Cylindrocarcinoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Cutaneous Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Spiradenocarcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Biological: Talimogene Laherparepvec
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: June 30th, 2016, 2:00pm GMT
Conditions: Melanoma; Merkel Cell Carcinoma; Other Solid Tumors
Interventions: Drug: TALIMOGENE LAHERPAREPVEC (TVEC); Radiation: Hypofractionated Radiotherapy
Sponsors: Memorial Sloan Kettering Cancer Center; Amgen
Recruiting
-
Posted: December 31st, 2015, 3:00pm GMT
Conditions: Head and Neck Squamous Cell Carcinoma; Breast Cancer; Sarcoma; Merkel Cell Carcinoma; Cutaneous T-Cell Lymphoma; Melanoma; Renal Cancer; Bladder Cancer; Prostate Cancer; Testicular Cancer; Solid Tumor
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Poly ICLC
Sponsors: Ludwig Institute for Cancer Research; MedImmune LLC; Cancer Research Institute, New York City
Recruiting
-
Posted: July 2nd, 2015, 2:00pm GMT
Condition: Various Advanced Cancer
Interventions: Drug: Nivolumab; Drug: Ipilimumab; Drug: Relatlimab; Drug: Daratumumab
Sponsors: Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting
-
Posted: June 24th, 2015, 2:00pm GMT
Conditions: Acquired Immunodeficiency Syndrome; BK Virus Infection; Human Immunodeficiency Virus; JC Virus Infection; Malignant Neoplasm; Merkel Cell Carcinoma; Merkel Cell Polyomavirus Infection; Viral Encephalitis
Interventions: Biological: Allogeneic BK-specific Cytotoxic T-lymphocytes; Other: Laboratory Biomarker Analysis
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
-
Posted: June 15th, 2015, 2:00pm GMT
Conditions: Dermatologic Conditions; Healthy Volunteers; Normal Volunteers; Carcinoma, Merkel Cell
Intervention:
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting
-
Posted: January 15th, 2021, 3:00pm GMT
Conditions: Gastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paraganglioma
Intervention: Drug: Lutetium [177Lu] oxodotreotide/dotatate
Sponsor: Advanced Accelerator Applications
Not yet recruiting
-
Posted: January 15th, 2021, 3:00pm GMT
Conditions: Brain Tumour; Glioma; Meningioma; Brain Metastases; Schwannoma
Intervention: Device: Intra-operative multispectral / hyperspectral analysis
Sponsor: Imperial College London
Not yet recruiting
-
Posted: January 14th, 2021, 3:00pm GMT
Conditions: Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Cancer
Interventions: Drug: Nivolumab; Drug: Ipilimumab; Drug: Carboplatin; Drug: Cabazitaxel
Sponsors: Andrew J. Armstrong, MD; Bristol-Myers Squibb
Not yet recruiting
-
Posted: January 13th, 2021, 3:00pm GMT
Conditions: Congenital Hyperinsulinism; Neuroblastoma; Parkinson Disease; Lewy Body Disease; Neuroendocrine Tumors; Brain Tumor
Interventions: Drug: 18F-DOPA; Drug: Furosemide Injection
Sponsor: University of Alberta
Not yet recruiting
-
Posted: January 12th, 2021, 3:00pm GMT
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Nab-paclitaxel Combined With Bevacizumab
Sponsors: Peking University; Qilu Pharmaceutical Co., Ltd.
Recruiting
-
Posted: January 11th, 2021, 3:00pm GMT
Condition: Neuroendocrine Prostate Cancer
Intervention: Drug: AMG 757
Sponsor: Amgen
Not yet recruiting
-
Posted: January 11th, 2021, 3:00pm GMT
Conditions: Unresectable Melanoma; Metastatic Melanoma; Stage III Melanoma; Stage IV Melanoma
Interventions: Drug: Sargramostim (GM-CSF); Drug: Pembrolizumab (anti-PD-1)
Sponsors: Dana-Farber Cancer Institute; Partner Therapeutics (PTx)
Not yet recruiting
-
Posted: January 8th, 2021, 3:00pm GMT
Conditions: Lung Small Cell Carcinoma; Neuroendocrine Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Biological: Dostarlimab; Drug: Niraparib
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting
-
Posted: January 6th, 2021, 3:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: Lanreotide autogel
Sponsors: Asan Medical Center; Samsung Medical Center; Seoul St. Mary's Hospital; Severance Hospital; Seoul National University Bundang Hospital
Recruiting
-
Posted: January 6th, 2021, 3:00pm GMT
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage IIA Cutaneous Melanoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab; Biological: Pembrolizumab; Biological: Quadrivalent Inactivated Influenza Vaccine; Procedure: Resection
Sponsor: Carlo Contreras
Not yet recruiting
-
Posted: January 5th, 2021, 3:00pm GMT
Conditions: Melanoma (Skin); Melanoma in Situ; Nevus Eye; Sebaceous Gland Carcinoma of the Eyelid; Basal Cell Carcinoma; Squamous Cell Carcinoma in Situ; Ocular Tumor
Intervention:
Sponsor: Peking University
Not yet recruiting
-
Posted: December 17th, 2020, 3:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: Telotristat Ethyl Oral Tablet
Sponsor: University of Chicago
Not yet recruiting
-
Posted: December 16th, 2020, 3:00pm GMT
Conditions: Stage IV Melanoma; Advanced Lung Cancer; Stage IV Non-small Cell Lung Cancer; Unresectable Non-Small Cell Lung Carcinoma; Unresectable Stage III Non-small-cell Lung Cancer; Immunotherapy; Immune Checkpoint Inhibitors; Small Cell Lung Cancer Extensive Stage
Interventions: Other: Educational Video and QPL List; Other: Usual Care
Sponsors: Massachusetts General Hospital; Conquer Cancer Foundation
Not yet recruiting
-
Posted: December 14th, 2020, 3:00pm GMT
Conditions: Functioning Lung Carcinoid Tumor; Locally Advanced Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Typical Carcinoid Tumor; Metastatic Lung Neuroendocrine Neoplasm; Non-Functioning Lung Carcinoid Tumor; Recurrent Lung Neuroendocrine Neoplasm; Unresectable Lung Neuroendocrine Neoplasm
Interventions: Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: December 2nd, 2020, 3:00pm GMT
Condition: Neuroendocrine Tumours (NET)
Intervention:
Sponsor: Ipsen
Not yet recruiting
-
Posted: November 26th, 2020, 3:00pm GMT
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma
Interventions: Other: Dietary Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
-
Posted: November 19th, 2020, 3:00pm GMT
Conditions: Chemotherapy; Anti-pd-1 Antibody; Cervical Neuroendocrine Carcinoma; Adverse Drug Event; Recurrent Cervical Carcinoma; Advanced Cervical Carcinoma; Objective Response Rate
Intervention: Drug: Drug therapy
Sponsor: Lei Li
Recruiting
-
Posted: November 10th, 2020, 3:00pm GMT
Condition: Neuroendocrine Tumors
Intervention:
Sponsors: Dr. Nayruz Knaana; Sheba Medical Center
Recruiting
-
Posted: November 10th, 2020, 3:00pm GMT
Conditions: Mucosal Melanoma; Neoadjuvant Treatment
Intervention: Drug: Lenvatinib, Pembrolizumab
Sponsor: Beijing Cancer Hospital
Not yet recruiting
-
Posted: November 9th, 2020, 3:00pm GMT
Condition: Cutaneous Malignant Melanoma
Interventions: Radiation: Low Dose Rate Brachytherapy (LDR); Drug: Nivolumab
Sponsor: Case Comprehensive Cancer Center
Not yet recruiting
-
Posted: November 4th, 2020, 3:00pm GMT
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Neuroendocrine Tumors
Interventions: Drug: Lutathera; Drug: Azedra
Sponsors: David Bushnell; National Institutes of Health (NIH); National Cancer Institute (NCI); Progenics Pharmaceuticals, Inc.
Not yet recruiting
-
Posted: October 30th, 2020, 2:00pm GMT
Condition: Gastroenteropancreatic Neuroendocrine Tumor
Interventions: Drug: Lutathera; Drug: Gallium 68 Dotatate; Procedure: Computed Tomography (CT); Procedure: Magnetic Resonance Imaging (MRI); Procedure: PET/CT
Sponsors: Stanford University; Advanced Accelerator Applications
Not yet recruiting
-
Posted: October 30th, 2020, 2:00pm GMT
Conditions: Pancreas Disease; Complication,Postoperative; PROMs; Pancreatic Fistula
Interventions: Procedure: Early drain removal; Procedure: Standard drain removal
Sponsor: IRCCS San Raffaele
Recruiting
-
Posted: October 27th, 2020, 2:00pm GMT
Conditions: Melanoma; Lung Cancer; Renal Cancer
Intervention: Behavioral: Tele-monitoring
Sponsor: Hospices Civils de Lyon
Not yet recruiting
-
Posted: October 19th, 2020, 2:00pm GMT
Conditions: Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8
Interventions: Drug: Cabazitaxel; Drug: Carboplatin; Biological: Cetrelimab; Drug: Niraparib
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting
-
Posted: October 19th, 2020, 2:00pm GMT
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage IIA Cutaneous Melanoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Hematopoietic and Lymphoid Cell Neoplasm; Invasive Malignant Neoplasm; Leukemia; Lymphoma; Malignant Solid Neoplasm; Pathologic Stage I Cutaneous Melanoma AJCC v8; Pathologic Stage IA Cutaneous Melanoma AJCC v8; Pathologic Stage IB Cutaneous Melanoma AJCC v8; Pathologic Stage II Cutaneous Melanoma AJCC v8; Pathologic Stage IIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIC Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Sarcoma; Stage I Colorectal Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage IIA Colorectal Cancer AJCC v8; Stage IIB Colorectal Cancer AJCC v8; Stage IIC Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8
Interventions: Other: Informational Intervention; Other: Internet Mobile Technology; Other: Internet-Based Intervention; Other: Questionnaire Administration; Procedure: Supportive Care
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Not yet recruiting
-
Posted: October 16th, 2020, 2:00pm GMT
Conditions: Merkel Cell Carcinoma; Small Cell Lung Cancer
Interventions: Biological: XmAb18087; Drug: XmAb18087 ± Pembrolizumab
Sponsors: Xencor, Inc.; ICON plc
Not yet recruiting
-
Posted: October 13th, 2020, 2:00pm GMT
Conditions: Pancreatic Cancer; Biliary Tract Cancer
Intervention:
Sponsor: Royal Surrey County Hospital NHS Foundation Trust
Not yet recruiting
-
Posted: October 12th, 2020, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Colorectal Cancer; Gastrointestinal Stromal Tumors; Pancreatic Cancer; Neuroendocrine Tumors; Unknown Primary Cancer; Digestive Cancer
Interventions: Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.; Drug: Other Therapy
Sponsors: Peking University; Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China
Recruiting
-
Posted: October 8th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumours; Neuroendocrine Tumour of the Lung; Small Intestinal NET
Intervention: Drug: Surufatinib
Sponsor: Hutchison Medipharma Limited
Not yet recruiting
-
Posted: October 8th, 2020, 2:00pm GMT
Conditions: Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma
Interventions: Drug: Surufatinib and Tislelizumab _ Part 1; Drug: Surufatinib and Tislelizumab _ Part 2
Sponsors: Hutchison Medipharma Limited; BeiGene
Not yet recruiting
-
Posted: September 28th, 2020, 2:00pm GMT
Condition: Melanoma
Intervention: Procedure: Biospecimen Collection
Sponsors: Ohio State University Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting
-
Posted: September 25th, 2020, 2:00pm GMT
Conditions: Metastatic Melanoma; Cognitive Impairment; Fatigue; Sleep; Depression, Anxiety; Quality of Life; Inflammation; Sickness Behavior; Cancer-related Cognitive Impairment
Intervention:
Sponsors: Aarhus University Hospital; University of Aarhus
Recruiting
-
Posted: September 24th, 2020, 2:00pm GMT
Conditions: Melanoma Stage III; Melanoma Stage IV; Inoperable Disease
Interventions: Drug: Interleukin-2; Drug: Ipilimumab; Drug: Nivolumab
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Clinigen, Inc.
Recruiting
-
Posted: September 22nd, 2020, 2:00pm GMT
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Drug: Dabrafenib Mesylate; Drug: Tazemetostat Hydrobromide; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: September 21st, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)
Intervention: Drug: Somatostatin analog
Sponsor: University of Aarhus
Recruiting
-
Posted: September 17th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Drug: Al18F-NOTA-octreotide; Device: PET/CT; Device: PET/MR
Sponsors: Universitaire Ziekenhuizen Leuven; University Hospital, Antwerp; University Hospital, Ghent; NETwerk, Belgium
Recruiting
-
Posted: September 10th, 2020, 2:00pm GMT
Conditions: Pancreatic Neuroendocrine Tumors; Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Intervention: Drug: 177Lu-DOTATATE
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: September 10th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Drug: Telotristat (Low-Dose); Drug: Telotristat (High-Dose)
Sponsors: Aman Chauhan; Lexicon Pharmaceuticals
Not yet recruiting
-
Posted: September 10th, 2020, 2:00pm GMT
Conditions: Malignant Melanoma; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms, Primary; Brain Neoplasms; Malignant Neoplasms
Interventions: Drug: PF-07284890; Drug: Binimetinib; Drug: Midazolam
Sponsor: Pfizer
Not yet recruiting
-
Posted: September 10th, 2020, 2:00pm GMT
Condition: Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Malignant Melanoma (MEL)
Intervention: Biological: GNR-051
Sponsor: AO GENERIUM
Recruiting
-
Posted: September 4th, 2020, 2:00pm GMT
Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma; Small Cell/Neuroendocrine
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: August 26th, 2020, 2:00pm GMT
Condition: Melanoma
Interventions: Drug: Tavo; Drug: Nivolumab; Device: OncoSec Medical Electroporation Therapy System
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; OncoSec Medical Incorporated
Recruiting
-
Posted: August 25th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumours (NET); Neuroendocrine Carcinomas (NEC)
Interventions: Drug: 177Lu-Dotatate; Drug: Nivolumab
Sponsors: Fundación de investigación HM; Syntax for Science, S.L
Recruiting
-
Posted: August 24th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Neuroendocrine Carcinoma
Intervention: Drug: Cabozantinib
Sponsor: Karsten Gavenis
Not yet recruiting
-
Posted: August 24th, 2020, 2:00pm GMT
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: arginine/lysine
Sponsor: Advanced Accelerator Applications
Not yet recruiting
-
Posted: August 20th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumor of Pancreas (Disorder); Neuroendocrine Tumor Grade 1
Intervention: Procedure: Radiofrequency ablation
Sponsor: Institut Paoli-Calmettes
Not yet recruiting
-
Posted: August 18th, 2020, 2:00pm GMT
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Procedure: Biospecimen Collection; Procedure: Dual X-ray Absorptiometry
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting
-
Posted: August 17th, 2020, 2:00pm GMT
Conditions: Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Neuroendocrine Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Neuroendocrine Carcinoma; Unresectable Pancreatic Adenocarcinoma
Interventions: Drug: Elimusertib; Drug: Irinotecan Sucrosofate; Drug: Topotecan Hydrochloride
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: August 17th, 2020, 2:00pm GMT
Conditions: Advanced Differentiated Thyroid Gland Carcinoma; Advanced Head and Neck Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Kaposi Sarcoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Prostate Carcinoma; Advanced Renal Cell Carcinoma; Advanced Thyroid Gland Medullary Carcinoma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; HIV Infection; Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Kaposi Sarcoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Prostate Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Differentiated Thyroid Gland Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Kaposi Sarcoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Thyroid Gland Medullary Carcinoma; Recurrent Triple-Negative Breast Carcinoma; Recurrent Urothelial Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8; Triple-Negative Breast Carcinoma
Interventions: Drug: Cabozantinib S-malate; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: August 14th, 2020, 2:00pm GMT
Condition: Pancreas Disease
Intervention:
Sponsor: Asian Institute of Gastroenterology, India
Recruiting
-
Posted: August 12th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Drug: 3-[18F]Fluoro-para-hydroxyphenethylguanidine; Drug: [123I] metaiodobenzylguanidine; Diagnostic Test: Positron emission tomography/computed tomography scan; Diagnostic Test: Planar scintigraphy scan; Diagnostic Test: Single photon emission computed tomography/computed tomography scan
Sponsor: University of Michigan Rogel Cancer Center
Recruiting
-
Posted: August 10th, 2020, 2:00pm GMT
Conditions: Appendix Carcinoma; Colon Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Rectal Carcinoma; Small Intestinal Carcinoma; Anal Carcinoma; Digestive System Carcinoma; Digestive System Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Procedure: Acupuncture Therapy; Procedure: Acupressure Therapy; Procedure: Oral Cryotherapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment
Sponsors: University of Washington; National Cancer Institute (NCI); The Safeway Foundation
Not yet recruiting
-
Posted: July 30th, 2020, 2:00pm GMT
Condition: Melanoma
Interventions: Procedure: Surgery; Procedure: Venepuncture
Sponsors: The Christie NHS Foundation Trust; University of Manchester
Recruiting
-
Posted: July 29th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Diagnostic Test: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT; Diagnostic Test: 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT
Sponsor: Peking Union Medical College Hospital
Recruiting
-
Posted: July 29th, 2020, 2:00pm GMT
Conditions: Head and Neck Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma
Intervention: Diagnostic Test: PD-L1 Kit
Sponsors: Pharmassist Ltd; University of Athens
Recruiting
-
Posted: July 27th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Carcinoma, Neuroendocrine
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: July 23rd, 2020, 2:00pm GMT
Conditions: Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Neuroendocrine Carcinoma
Intervention: Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
-
Posted: July 20th, 2020, 2:00pm GMT
Conditions: Non-colorectal Cancer (Esophagus, Stomach, Liver/Bile Ducts, Pancreas, Neuroendocrine Carcinoma); Colorectal With Associated Risk Factors
Intervention: Other: multidisciplinary assessment and intervention
Sponsor: Institut Curie
Not yet recruiting
-
Posted: July 17th, 2020, 2:00pm GMT
Conditions: Pancreatic Cancer; Oesophageal Cancer; Colon Cancer; Liver Cancer; Rectal Cancer; Bile Duct Cancer; GIST, Malignant; Neuroendocrine Tumors; Small Intestine Cancer; Gastric Cancer
Intervention: Other: No intervention - observational study only
Sponsor: University Medicine Greifswald
Recruiting
-
Posted: July 15th, 2020, 2:00pm GMT
Condition: Small-cell Lung Cancer
Intervention: Drug: HPN328
Sponsor: Harpoon Therapeutics
Recruiting
-
Posted: July 10th, 2020, 2:00pm GMT
Conditions: Cardiovascular Disorder; Chronic Kidney Disease; Metastatic Renal Cell Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Interventions: Other: Best Practice; Other: Blood Pressure Measurement; Other: Clinical Management; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Not yet recruiting
-
Posted: July 9th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Neuroendocrine Neoplasm; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Carcinoma
Intervention: Drug: Somatostatin analog; chemotherapy
Sponsor: University of Roma La Sapienza
Recruiting
-
Posted: July 8th, 2020, 2:00pm GMT
Condition: Mucosal Melanoma
Interventions: Combination Product: Toripalimab; Combination Product: Temozolomide
Sponsor: Beijing Cancer Hospital
Recruiting
-
Posted: July 8th, 2020, 2:00pm GMT
Conditions: Advanced Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Melanoma of Unknown Primary; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Acral Lentiginous Melanoma; Unresectable Melanoma; Unresectable Mucosal Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab; Other: Patient Observation; Biological: Pembrolizumab
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
-
Posted: July 7th, 2020, 2:00pm GMT
Conditions: Bladder Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Hepatocellular Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Pleural Neoplasm; Malignant Skin Neoplasm; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Thymus Neoplasm; Neuroendocrine Neoplasm; Thyroid Gland Carcinoma; Urothelial Carcinoma
Interventions: Procedure: Computed Tomography; Drug: Gallium Ga 68 FAPi-46; Procedure: Positron Emission Tomography
Sponsor: Jonsson Comprehensive Cancer Center
Recruiting
-
Posted: June 30th, 2020, 2:00pm GMT
Condition: Large-Cell Neuroendocrine Carcinoma
Interventions: Other: Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma; Other: Treatment for Small Cell Lung Cancer
Sponsor: Aman Chauhan
Recruiting
-
Posted: June 30th, 2020, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Urothelial Carcinoma; Malignant Melanoma; Head and Neck Squamous Cell Carcinoma
Interventions: Drug: CAN04; Drug: Pembrolizumab
Sponsor: Cantargia AB
Recruiting
-
Posted: June 23rd, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; COVID-19
Intervention:
Sponsor: European Institute of Oncology
Recruiting
-
Posted: June 19th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: 64Cu-SARTATE
Sponsor: Clarity Pharmaceuticals Ltd
Not yet recruiting
-
Posted: June 19th, 2020, 2:00pm GMT
Conditions: Non-small Cell Lung Cancer; Melanoma
Intervention: Diagnostic Test: [99mTc]-NM01 SPECT
Sponsors: Guy's and St Thomas' NHS Foundation Trust; NanoMab
Not yet recruiting
-
Posted: June 16th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Adrenal Tumor
Intervention: Other: No intervention
Sponsor: University of Pennsylvania
Not yet recruiting
-
Posted: June 12th, 2020, 2:00pm GMT
Conditions: Metastatic Well Differentiated Neuroendocrine Neoplasm; Neuroendocrine Tumors
Interventions: Drug: Cabozantinib; Drug: Lanreotide
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
-
Posted: June 12th, 2020, 2:00pm GMT
Condition: Patients With Small Cell Lung Carcinoma and Other Neoplasms
Intervention: Drug: BI 764532
Sponsor: Boehringer Ingelheim
Recruiting
-
Posted: June 2nd, 2020, 2:00pm GMT
Condition: High Grade Neuroendocrine Neoplasms
Interventions: Drug: Cabozantinib; Procedure: Blood for plasma biomarkers
Sponsors: Washington University School of Medicine; Exelixis
Recruiting
-
Posted: May 29th, 2020, 2:00pm GMT
Conditions: Colitis; Lung Non-Small Cell Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Melanoma
Interventions: Biological: Infliximab; Biological: Vedolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
-
Posted: May 25th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumor; Anaplastic Thyroid Cancer; Adenocarcinoma; Pheochromocytoma; Paraganglioma
Intervention: Drug: Cabozantinib 40 mg
Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Ipsen; Roche Pharma AG
Recruiting
-
Posted: May 20th, 2020, 2:00pm GMT
Conditions: Advanced Adrenal Gland Pheochromocytoma; Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma
Interventions: Drug: Olaparib; Other: Quality-of-Life Assessment; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: May 18th, 2020, 2:00pm GMT
Condition: Pituitary Adenoma
Intervention: Drug: 5-aminolevulinic acid
Sponsors: Massachusetts General Hospital; NX Development Corp
Not yet recruiting
-
Posted: May 15th, 2020, 2:00pm GMT
Condition: Advanced Cancer
Intervention: Combination Product: X-PACT
Sponsor: Immunolight, LLC
Not yet recruiting
-
Posted: May 13th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: 177Lu-Dotatate
Sponsor: IRCCS San Raffaele
Recruiting
-
Posted: May 13th, 2020, 2:00pm GMT
Conditions: Solid Tumor; Melanoma
Interventions: Biological: OH2 injection; Drug: Keytruda
Sponsor: Wuhan Binhui Biotechnology Co., Ltd.
Recruiting
-
Posted: May 5th, 2020, 2:00pm GMT
Conditions: Clinical Trial, Phase I; Neuroendocrine Tumors; Thymoma; Mesothelioma
Intervention: Drug: 177Lu-DOTA-TATE + olaparib
Sponsors: Vastra Gotaland Region; Advanced Accelerator Applications
Recruiting
-
Posted: May 5th, 2020, 2:00pm GMT
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Cutaneous Melanoma; Metastatic Cutaneous Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Cutaneous Melanoma
Interventions: Drug: Binimetinib; Biological: Nivolumab; Other: Questionnaire Administration
Sponsor: Jonsson Comprehensive Cancer Center
Recruiting
-
Posted: April 28th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: platinum chemotherapy
Sponsors: Assistance Publique - Hôpitaux de Paris; Ipsen
Recruiting
-
Posted: April 27th, 2020, 2:00pm GMT
Condition: Gastrointestinal Neoplasms
Interventions: Biological: Blood sampling; Procedure: Liver biopsy; Biological: Stool collect
Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting
-
Posted: April 27th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Liver Metastases
Intervention: Radiation: TheraSpheres Selective Internal Radiation Therapy (SIRT)
Sponsors: Imperial College London; Biocompatibles UK Ltd, a BT International group company
Recruiting
-
Posted: April 22nd, 2020, 2:00pm GMT
Condition: Melanoma
Intervention: Biological: Super circulating tumor infiltrating lymphocytes(ScTIL)
Sponsor: Beijing Cancer Hospital
Not yet recruiting
-
Posted: April 20th, 2020, 2:00pm GMT
Conditions: Melanoma; Melanoma (Skin); Moles; Nevus; Nevus, Blue; Nevus, Pigmented; Nevus, Spitz; Nevi, Spindle Cell; Nevi, Dysplastic; Dysplastic Nevus Syndrome; Mucosal Melanoma; Mucosal Melanosis
Intervention: Procedure: Non-invasive adhesive system (patch)
Sponsors: Russian Academy of Medical Sciences; Blokhin's Russian Cancer Research Center
Recruiting
-
Posted: April 15th, 2020, 2:00pm GMT
Conditions: Prostate Cancer; Advanced Prostate Carcinoma
Interventions: Drug: Hyperpolarized C13; Procedure: Magnetic Resonance Imaging (MRI)
Sponsors: Rahul Aggarwal; National Cancer Institute (NCI)
Recruiting
-
Posted: April 14th, 2020, 2:00pm GMT
Conditions: Covid-19; Lung Cancer
Intervention:
Sponsor: Spanish Lung Cancer Group
Recruiting
-
Posted: April 8th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumor Grade 2; Neuroendocrine Tumors
Interventions: Drug: Capecitabine Oral Product; Drug: Temozolomide Oral Product; Combination Product: transarterial radioembolization
Sponsor: University of Pennsylvania
Not yet recruiting
-
Posted: April 7th, 2020, 2:00pm GMT
Conditions: Pancreas Neoplasm; Neuroendocrine Tumors
Intervention: Procedure: Portal vein resection / reconstruction
Sponsor: Royal Free Hospital NHS Foundation Trust
Not yet recruiting
-
Posted: April 6th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Diagnostic Test: Copper Cu 64 Dotatate
Sponsor: Curium US LLC
Available
-
Posted: March 31st, 2020, 2:00pm GMT
Conditions: Metabolic Syndrome; Overweight or Obesity; PreDiabetes; Weight Loss; Quality of Life
Intervention: Behavioral: Time-Restricted Eating
Sponsors: Nicolaus Copernicus University; Salk Institute for Biological Studies; University of California, San Diego; Center for Obesity and Metabolic Disorders Treatment Bydgoszcz
Recruiting
-
Posted: March 27th, 2020, 2:00pm GMT
Condition: Neuroendocrine Carcinoma
Interventions: Drug: FOLFOXIRI Protocol; Drug: Cisplatin injection
Sponsors: Centre Hospitalier Universitaire Dijon; National Cancer Institute, France
Recruiting
-
Posted: March 27th, 2020, 2:00pm GMT
Condition: Neuroendocrine Neoplasms (Tumours)
Intervention:
Sponsors: King's College Hospital NHS Trust; Ampersand Health Ltd; Neuroendocrine Cancer UK
Recruiting
-
Posted: March 24th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Diagnostic Test: Gallium-68 NODAGA-LM3 PET/CT; Diagnostic Test: Gallium-68 DOTA-LM3 PET/CT; Diagnostic Test: Gallium-68 DOTATATE PET/CT
Sponsor: Peking Union Medical College Hospital
Recruiting
-
Posted: March 19th, 2020, 2:00pm GMT
Conditions: Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Hematopoietic and Lymphoid Cell Neoplasm; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Refractory Plasma Cell Myeloma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Interventions: Procedure: Biospecimen Collection; Other: Medical Chart Review
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: March 2nd, 2020, 3:00pm GMT
Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Merkel Cell Carcinoma, Stage III; Neuroendocrine Tumors; Carcinoma Neuroendocrine Skin
Interventions: Drug: Avelumab; Drug: Placebo
Sponsor: Melanoma and Skin Cancer Trials Limited
Recruiting